Long-term stem cell culture with organoid formation is a platform for studying the mechanisms of stem cell regulation 1-3 . In the lung, AT2 cells produce pulmonary surfactant and function as tissue stem cells, contributing to the homeostasis of alveoli 4,5 . Dysfunction of AT2 cells is associated with life-threatening lung disorders, including chronic obstructive pulmonary disease 6 , pulmonary fibrosis 7,8 and lung cancer 9 . Despite the high demand for research on the mechanisms underlying such diseases and for the discovery of new drugs, applications involving human AT2 cells have been limited because of the unavailability of these primary cells and the difficulty of their expansion 10, 11 .
Long-term stem cell culture with organoid formation is a platform for studying the mechanisms of stem cell regulation [1] [2] [3] . In the lung, AT2 cells produce pulmonary surfactant and function as tissue stem cells, contributing to the homeostasis of alveoli 4, 5 . Dysfunction of AT2 cells is associated with life-threatening lung disorders, including chronic obstructive pulmonary disease 6 , pulmonary fibrosis 7, 8 and lung cancer 9 . Despite the high demand for research on the mechanisms underlying such diseases and for the discovery of new drugs, applications involving human AT2 cells have been limited because of the unavailability of these primary cells and the difficulty of their expansion 10, 11 .
hiPSCs are a potential source of AT2 cells. Although the stepwise induction of AT2 cells from pluripotent stem cells (PSCs) has been reported [12] [13] [14] [15] [16] [17] [18] , there have been no reports on the stable expansion of PSC-derived AT2 cells. In the present study, we developed a method for the efficient induction and long-term expansion of hiPSC-derived alveolar stem cells in AOs. We used long-term expanded AOs in drug toxicology studies, thus providing a new platform for studying drug-induced alveolar injury in vitro.
results

Generation of alveolar organoids harboring hiPsc-derived sFtPc + cells
We previously reported the induction of AT2 cells 17 from isolated CPM + 'ventralized' anterior foregut endoderm (VAFE) cells, but the induction efficiency in that experiment remained low. Considering previous reports indicating that 'distal tip' cells in later stages of lung development differentiate into only alveolar epithelial cells 19 , we hypothesized that 'preconditioning' NKX2-1 + VAFE cells with a treatment that mimicked the microenvironment of distal tip cells before alveolar differentiation might increase AT2 cell differentiation.
After inducing NKX2-1-enriched VAFE cells in two-dimensional (2D) culture as previously described 17, 20 , we tried to identify such a preconditioning treatment. We examined various media including growth factors and small molecules related to lung development 21, 22 and identified the combination of CHIR99021, FGF10, KGF and DAPT (CFKD) as suitable for preconditioning the NKX2-1 + VAFE cells (present at 85.2% ± 5.6% (mean ± s.e.m.) of total cells at day 21) (Supplementary Fig. 1a-c) . We determined that a 1-week treatment with CFKD was optimal for the induction of SFTPC (an AT2-cell-specific marker) ( Supplementary Fig. 1d ,e).
We were able to purify the preconditioned NKX2-1 + cells to approximately 90% in a CPM hi cell population by using fluorescence-activated cell sorting (FACS) in three hiPSC lines and one human embryonic stem cell line; however, the fraction of NKX2-1 + cells was small in the CPM lo and CPM − populations ( Supplementary Fig. 1f-h ). After three-dimensional (3D) coculture of CPM hi cells with human fetal lung fibroblasts, AOs formed in Matrigel (Fig. 1a,b) . On day 35, we visualized lamellar-body-like organelles, a specific feature of AT2 cells 4, 23 , by transmission electron microscopy (TEM) (Fig. 1c) . For further evaluation, we examined the uptake of BODIPY-labeled phosphatidylcholine, a major component of pulmonary surfactant, into apical vesicles labeled with LysoTracker Red. We observed that uptake occurred at levels similar to that in adult AT2 cells 24 ( Fig. 1d,  Supplementary Fig. 1i ). Next, we used flow cytometry to analyze AOs generated from SFTPC-GFP + reporter hiPSCs. We observed 51.2% ± 1.2% induction efficiency of SFTPC + cells with one fetal human lung fibroblast line (Fig. 1e, Supplementary Fig. 1j ). With respect to the generality of this approach, we induced SFTPC + cells in cocultures with four other human lung fibroblast lines (three fetal and one adult), whereas almost no SFTPC + cells were induced among human dermal fibroblasts ( Supplementary  Fig. 1k,l) . Immunofluorescence analysis showed that EpCAM + cell spheroids harboring SFTPC + cells were surrounded by vimentin + mesenchymal cells without CD31 + endothelial cells (Fig. 1f,  Supplementary Fig. lm ) and expressed various AT1 (PDPN) and AT2 (SFTPA, SFTPB, SFTPC, SFTPD, ABCA3 and DCLAMP) markers (Fig. 1g,h ). Each AT1 (AQP5) and AT2 marker was robustly detected in PSC-derived AOs by qRT-PCR (Fig. 1i) , whereas proximal airway marker expression was low or nonexistent ( Supplementary Fig. 2 ).
hiPsc-derived sFtPc + cells resemble At2 cells
Global gene expression analysis demonstrated that 740 genes were significantly (P < 0.05) upregulated in the SFTPC + cells compared with their expression in both SFTPC -cells in AOs and CPM hi progenitor cells (Supplementary Fig. 3a , Supplementary Table  1) . These 740 genes were annotated with 75 Gene Ontology (GO) terms ( Supplementary Fig. 3b,c) , including "alveolar lamellar body" and "surfactant homeostasis," which specifically characterize AT2 cells (P = 0.00046 and P = 0.000068, respectively) ( Supplementary Fig. 3d ). We immunologically detected several representative AT2 markers among the top 25 upregulated genes ( Supplementary Fig. 3e ) in SFTPC + and DCLAMP + cells of hiPSC-derived AOs ( Supplementary Fig. 4 ). Taken together, these results suggest that the global gene expression patterns of hiPSCderived SFTPC + cells are consistent with those of AT2 cells.
single-cell analysis of preconditioned Psc-derived progenitor cells
To better define the preconditioning of VAFE cells by CFKD treatment ( Supplementary Fig. 1a) , we isolated CPM + progenitor cells before and after CFKD treatment and carried out single-cell (sc) RNA-seq analysis. We compared the transcriptomes of 71 and 85 CPM hi cells before and after CFKD treatment (days 14 and 21), respectively, with those of 50 SFTPC + cells 5 d after AO induction (day 26) (Fig. 2a, Supplementary Fig. 5a-d) . Progenitor markers (CPM, NKX2-1 and FOXA2) were expressed in most cells, whereas AT2 markers were rarely expressed in CPM hi progenitor cells (Fig. 2b) (Fig. 2c, Supplementary Fig. 5e ).
When we compared the transcriptomes of CPM hi cells before and after CFKD treatment, we noted that the expression of 680 genes was significantly changed after treatment (more than twofold; P < 0.05, ANOVA) (Supplementary Table 2) . We clustered those genes into gene sets that clearly distinguished the differences in expression profiles among the three conditions: CPM hi cells before and after CFKD treatment, and SFTPC + cells (Fig. 2d) . Notably, one of these clusters involved the key genes, defined as those whose expression increased in a stepwise fashion (more than twofold; P < 0.05, ANOVA) between day 14 and day 21 and between day 21 and day 26 during SFTPC + cell differentiation (Supplementary Table 2 ). KEGG pathway analysis showed that the genes involved in this cluster were strongly associated with the Wnt, MAPK and Hippo pathways, which have been reported as upregulated in alveolar differentiation or lung branching morphogenesis [25] [26] [27] . ETV5 and CEBPD, both known to be expressed in developing AT2 cells 28, 29 , were clustered in the key gene set. In contrast, the expression of markers of distal tip progenitor cells (SOX9 and ID2) and proximal progenitor cells (SOX2 and TP63) did not change drastically during SFTPC + cell differentiation (Fig. 2e) .
Fibroblast-free induction of sFtPc + cells
For fibroblast-free (FF) induction of SFTPC + cells, we screened single or combination treatments of growth factors and small molecules by adding each reagent to the basal medium supplemented with dexamethasone, 8-Br-cAMP, 3-isobutyl-1-methylxanthine, KGF and Y27632 (DCIK 30 +Y 31 ) to differentiate the preconditioned CPM hi progenitor cells to SFTPC + cells in a droplet culture of B2-3 hiPSC-derived CPM hi progenitor cell aggregates (Fig.  3a) . We observed that the addition of CHIR99021 (a canonical Wnt pathway agonist that acts by inhibiting GSK-3β) 25, 32 and SB431542 (an inhibitor of TGF-β receptor kinase) 33 (2i) to DCIK+Y was optimal for the generation of fibroblast-free AOs (FF-AOs) harboring SFTPC + cells with lamellar bodies (Fig. 3b,c) . By flow cytometry, 2i treatment induced SFTPC + cells at 23.1% ± 1.4% (Fig. 3d, Supplementary Fig. 6a ), whereas the induction efficiency was lower with single inhibition. We observed expression of various AT2 markers in FF-AOs similar to that in fibroblast-dependent AOs (FD-AOs) (Fig. 3e, Fig. 1i) . Especially, the expression of SFTPA2, SFTPC and DCLAMP (LAMP3) increased significantly (P < 0.05) in 2i-treated FF-AOs derived from multiple PSC lines compared with that in vehicle-treated controls (days [21] [22] [23] [24] [25] [26] [27] [28] . For deeper evaluation, we carried out scRNA-seq of fibroblast-free SFTPC + (FF-SFTPC + ) cells (Supplementary Fig.  6b-f (Fig. 3f) . Several AT2 markers were expressed similarly in FF-SFTPC + and FD-SFTPC + cells and adult AT2 cells, although the fraction of cells that expressed ABCA3 seemed to be relatively lower in both FF-SFTPC + cells and adult AT2 cells than in FD-SFTPC + cells (Fig. 3g) . Thus, although FF-SFTPC + and FD-SFTPC + cells both showed gene expression profiles consistent with that of AT2 cells, specific AT2 marker gene expression was affected by the induction method.
long-term expansion of hiPsc-derived Fd-sFtPc + cell populations
We succeeded in the long-term expansion of FD-SFTPC + cell populations by repeating organoid formation with isolated FD-SFTPC + cells in a manner similar to that used for the initial formation of FD-AOs ( Fig. 7a ), and the population-doubling level of FD-SFTPC + cells increased linearly to 17.7 ± 0.95 until 12 weeks after the starting passages ( Supplementary Fig. 7b ) with normal karyotypes ( Supplementary Fig. 7c ). The population-doubling time of the FD-SFTPC + cells tended to be shorter during later passages, whereas that of the EpCAM + cells showed no substantial changes (Fig. 4b) . Expanded FD-SFTPC + cell populations (third and sixth passages (P3 and P6)) maintained DCLAMP expression, whereas we observed SFTPC -PDPN + AQP5 + AT1-like cells in FD-AOs (P3 and P6) (Fig. 4c,d, Supplementary Fig. 7d ,e).
Morphologically, numerous lamellar bodies were maintained in the apical side of the P2 and P5 FD-AOs, and these seemed to be more mature in terms of frequency, density and size than those in the FD-AOs on day 35 ( Fig. 4e) . We detected progressive changes in the lamellar bodies by flow cytometry with LysoTracker ( Supplementary Fig. 7f ). Nonbiased PCA and hierarchical clustering analysis of the transcriptomes of the expanded P0, P2 and P5 FD-SFTPC + cells, primary isolated human adult AT2 cells, CPM hi progenitor cells and hiPSC-derived proximal airway epithelial cells (PAECs) 20 showed that the transcriptomes of FD-SFTPC + cells were closer to those of the primary adult AT2 cells than to those of CPM hi progenitor cells or hiPSC-derived PAECs, regardless of the number of passages (Fig. 4f, Supplementary Fig. 8a,b) . Table 3 ) also indicated similarities in AT2 marker gene expression in hiPSCderived P0, P2 and P5 FD-SFTPC + cells and primary adult AT2 cells (Fig. 4g, Supplementary Fig. 8c ). We also evaluated the differences between the transcriptomes of hiPSC-derived FD-SFTPC + cells and adult AT2 cells. We observed that the Articles hiPSC-derived FD-SFTPC + cells showed remarkable downregulation of immune system genes, such as major histocompatibility complex (MHC) class II genes, which are known to be expressed in adult AT2 cells 35 ( Supplementary Fig. 9a, 
Hierarchical clustering and correlation analysis of representative markers of lung epithelial cells (Supplementary
b, Supplementary Tables 4 and 5).
For long-term expansion without SFTPC reporter cell lines, we developed an alternative method for passaging PSC-derived alveolar stem cells using LysoTracker, which is reported to be useful for isolating adult AT2 cells 36 ( Supplementary  Fig. 10a ). Because hiPSC-derived FD-SFTPC + cells accumulated more LysoTracker than other cells did ( Supplementary  Fig. 10b) , we isolated an EpCAM + LysoTracker hi cell population as alveolar stem cells, thus demonstrating that FD-AOs derived from EpCAM + LysoTracker hi cells and passaged without genetic reporter cell lines maintained AT1 and AT2 markers ( Supplementary Fig. 10c,d ) as well as lamellar-body-like organelles (Supplementary Fig. 10e ).
cellular heterogeneity of Fd-sFtPc + cells
Recent studies in mice revealed that SFTPC + cell populations are heterogeneous, including SFTPC + PDPN + cells, which are defined as bipotent, with the potential to differentiate into either AT1 or AT2 cells 9, 37 . Because we also detected SFTPC + PDPN + cells among SFTPC + PDPN -cells in our cultures (Fig. 5a,  Supplementary Fig. 11a,b) , we hypothesized that the expanded hiPSC-derived FD-SFTPC + cell populations may also have included bipotent-like cells.
By TEM, we detected three types of SFTPC + cells consistent with previous observations of lung development 9, 38 : 'immature' type, with large glycogen vacuole-like structures and no lamellar bodies; 'early' type, with large glycogen vacuole-like structures and small lamellar bodies; and 'late' type, with large lamellar bodies and small glycogen vacuoles (Supplementary Fig. 11c ). We carried out scRNA-seq of isolated P0, P2 and P5 FD-SFTPC + cells (Supplementary Fig. 12 ) as previously described 39 . Examination of known AT1 markers in 138 FD-SFTPC + single cells showed three distinct subpopulations, although the expression of AT2 markers seemed homogeneous among them (Fig. 5b) . We further validated AT1 and AT2 marker expression in SFTPC + cells by immunofluorescence and qRT-PCR (Supplementary Fig. 13a,b) .
We classified the FD-SFTPC + cells into three groups on the basis of their expression of the AT1 markers (high, moderate and low). The fractions of the three classified cell populations were not significantly changed among P0, P2 and P5 FD-SFTPC + cells (Supplementary Fig. 13c ). Nonbiased PCA of transcriptome data from P0, P2 and P5 FD-SFTPC + cells identified a bidirectional distribution of the cells (Fig. 5c, Supplementary Fig. 13d,e) . Plots of PCA loading scores of the marker genes for these cells revealed that each AT1 marker was localized in low PC1 and PC2 areas (Fig. 5d) , consistent with the bidirectional distribution of single FD-SFTPC + cells. Hierarchical clustering of the 144 genes with significantly different expression (P < 0.05, ANOVA; more than twofold change) between AT1-marker hi and AT1-marker lo cells revealed three distinct gene sets with different GO profiles (Fig. 5e, Supplementary Fig. 14a, Supplementary Table 6 ). These gene sets involved AT1 markers listed in the LungGENS database of scRNA-seq data for fetal mouse lung (embryonic day 18.5 (E18.5)) 40 ; clusters 1 and 2 were particularly enriched in these genes, which suggests that they might involve key markers of AT1 cell differentiation.
To test whether these gene sets identify SFTPC + cell subpopulations that are relevant in vivo, we used the gene sets to classify single Sftpc + cells in samples of lung tissue from E18.5 and adult mice, obtained from a previous study 37 . We classified 106 Sftpc + cells (60 from E18.5 mice, 46 from adult mice) into clusters that reflected AT1-marker enrichment ( Supplementary  Fig. 14b ), demonstrating that hiPSC-derived FD-SFTPC + cell populations included bipotent-like cells that expressed AT1 and AT2 markers and whose transcriptomes more closely resembled those of a major portion of Sftpc + cells from E18.5 mice than from adult mice.
Alveolar organoids as drug toxicology models
For the application of hiPSC-derived FD-AOs to in vitro drug toxicology studies, we focused on two drugs, amiodarone and GNE7915, both of which are known to induce unusually enlarged lamellar bodies in AT2 cells in vivo. Amiodarone is a widely used anti-arrhythmia agent notorious for causing druginduced interstitial pneumonia 41 . GNE7915 is a small-molecule inhibitor of LRRK2, a kinase expressed by a causative gene of familial Parkinson's disease 42 . Although enlarged lamellar bodies have been reported in Lrrk2-knockout rodents and GNE7915-treated primates, no interstitial pneumonia was observed [43] [44] [45] . We treated P2 or P3 FD-AOs with 5 µM GNE7915 and 10 µM amiodarone for 10 d (Fig. 6) . The lamellar bodies in treated FD-AOs were remarkably enlarged and increased, suggesting that we had recapitulated a cell-specific phenotype of AT2 cells in vivo (Fig. 6b) . In live cell imaging, we observed numerous and enlarged LysoTracker-labeled organelles in SFTPC + cells treated with GNE7915 and amiodarone (Fig. 6c) . We quantified the phenotypic changes in drug-treated FD-AOs by analyzing the fluorescent-signal intensity of LysoTracker and found that drugtreated SFTPC + cells accumulated significantly (P < 0.05) more LysoTracker than control samples did (Fig. 6e) . EpCAM + SFTPCcells and EpCAM -fibroblasts were also significantly affected by amiodarone but were not markedly affected by GNE7915 (Fig. 6e) , which suggests that different mechanisms might cause Articles the abnormalities induced by these drugs, despite the morphological resemblance. For further evaluation, we compared the transcriptomes of isolated SFTPC + cells from GNE7915-treated or amiodaronetreated FD-AOs with those of vehicle-treated control cells. We identified three categories of genes: 'common' , for overlapping genes, and '+amiodarone' and '+GNE7915' , which included genes significantly (P < 0.05) affected by the respective drugs compared with expression in the vehicle-treated control ( Supplementary  Fig. 15, Supplementary Table 7) . GO analysis showed that each category had distinct gene profiles (Supplementary Table 8 ). Amiodarone-treated SFTPC + cells showed particularly marked changes in the expression of genes annotated for wound healing, cytokine secretion and IL-6 production, whereas GNE7915-treated cells showed changes in the expression of genes associated with development. These differences between the effects of amiodarone and of GNE7915 may partially reflect the more severe phenotype in amiodarone-induced lung injury in vivo. discussion Here we established efficient and robust induction of alveolar stem cells from hiPSCs by adding a step for the preconditioning of progenitor cells to our previous protocol 17 . The induction efficiency of SFTPC + cells was substantially improved in all the analyzed cell lines, including 585A1, from which it was difficult to induce SFTPC + cells in our previous study 17 , thus indicating the robustness of our newly developed protocol (Supplementary Table 9 ). We also report, to our knowledge for the first time, a method for the long-term culture of SFTPC + alveolar stem cells. Although previous efforts to induce PAECs from PSCs without mesenchymal cells were successful 18, 20 , coculture with fibroblasts proved advantageous for the induction and stable expansion of SFTPC + cell populations while maintaining their stem cell properties, which suggests that the 'niche' provided by epithelial-mesenchymal interaction may be crucial for maintenance of the 'stemness' of AT2 cells 5, 46, 47 . We note that, although not characterized in as much detail as we provide here, the induction of SFTPC + cells without mesenchymal cells has recently been reported by others 18 .
The discrepancy in the expression levels of several AT2 markers between FF-SFTPC + and FD-SFTPC + cells indicates that other factors besides Wnt and TGF-β signaling-pathway regulators would be involved in the differentiation of alveolar stem cells. Long-term expansion and further characterization of FF-SFTPC + cells are still needed and will be the subject of future studies. Interestingly, although hiPSC-derived SFTPC + cells had a gene expression profile that included the representative AT2 markers and morphologically mature lamellar bodies, they lacked expression of genes associated with the immune system such as MHC class II genes, which suggests that interaction with immune cells, such as macrophages 48 , might be required for further maturation for host defense 49 . scRNA-seq elucidated the heterogeneity of alveolar stem cells derived from hiPSCs. AT1-marker-based gene set enrichment analysis of hiPSC-derived FD-SFTPC + single-cell transcriptomes showed that the gene expression patterns of these cells resembled those of Sftpc + mouse cells in the late gestation phase, rather than those of Sftpc + lung cells from adult mice. In conclusion, the long-term culture of hiPSC-derived alveolar stem cells containing heterogeneous AT2 cells in organoids may be a viable method for the modeling of human alveolar development. Furthermore, the methods described are applicable to drug toxicology tests, enabling cell-based phenotyping and transcriptomic analysis of hiPSC-derived AT2 cells affected by chemical agents.
methods
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
online methods A step-by-step protocol is provided as a Supplementary Protocol and is also available at Protocol Exchange 50 .
Maintenance of human PSCs. H9 human embryonic stem cells (hESCs) 51 and 409B2, 648A1, 585A1, 604A1, 201B7 (refs. 52-54) and derivative B2-3 SFTPC-GFP reporter hiPSCs 17 were maintained on STO feeder cells in Primate ES medium (ReproCELL) supplemented with 4 ng/ml human FGF-2 (DS Pharma Biomedical) and 50 U/ml penicillin-streptomycin (Life Technologies). For the 409B2, 585A1, 201B7 and B2-3 cell lines, hiPSCs were cultured without feeder cells in Essential 8 medium (Life Technologies) before differentiation studies, as described previously 20 . The use of H9 hESCs was approved by MEXT of Japan. Every cell line was tested for mycoplasma contamination with the MycoAlert mycoplasma detection kit (Lonza); no contamination was detected in any cell line.
Induction and isolation of NKX2-1 + lung progenitor cells. We carried out stepwise differentiation of human PSCs into VAFE cells as previously described 17, 20 . Briefly, for the induction of definitive endodermal cells, undifferentiated PSCs incubated in 10 µM Y27632 (LC Laboratories) for 1 h were dissociated with Accutase (Innovative Cell Technologies), then seeded on plates coated with Geltrex (Life Technologies) at a density of 1.375 × 10 5 cells/cm 2 for feeder-free PSCs or 1.1 × 10 5 cells/cm 2 for feederdependent PSCs in RPMI 1640 medium (Nacalai Tesque) containing human activin A (100 ng/ml; Peprotech), CHIR99021 (1 µM; Axon Medchem), Y27632 (10 µM), 2% B-27 supplement (Life Technologies; 17504-044) and 50 U/ml penicillin-streptomycin. The medium was replaced on days 2 and 4 without Y27632. Sodium butyrate was supplemented at a dose of 0.25 mM on day 1 and 0.125 mM on days 2 and 4. For anteriorization, definitive endodermal cells were treated with human Noggin (100 ng/ml; HumanZyme) and SB431542 (10 µM; Stem RD) in the GlutaMAXsupplemented DMEM/F12 basal medium (Life Technologies) containing 2% B-27 supplement, 50 U/ml penicillin-streptomycin, l-ascorbic acid (0.05 mg/ml; Wako) and monothioglycerol (0.4 mM; Wako) from day 6 to day 10. For ventralization, the cells were then treated with human BMP4 (20 ng/ml; HumanZyme) and the following doses of all-trans retinoic acid (ATRA; SigmaAldrich) and CHIR99021 from day 10 to day 14. The optimized ATRA/CHIR99021 doses were 0.5 µM/3.5 µM (H9 hESCs), 0.05 µM/3.0 µM (201B7 and B2-3 hiPSCs), 0.5 µM/3.5 µM (585A1 hiPSCs), 1.0 µM/2.5 µM (604A1 hiPSCs), 1.0 µM/2.5 µM (648A1 hiPSCs) and 0.1 µM/2.5 µM (409B2 hiPSCs). For preconditioning toward alveolar stem cell differentiation, NKX2-1 + VAFE-enriched cells were cultured in the same basal medium supplemented with CHIR99021 (3 µM), human FGF10 (10 ng/ml; Wako), human KGF (10 ng/ml; Prospec) and DAPT (20 µM; Stem RD) from day 14 to day 21 after the evaluation of several combinations of each factor and each culture duration.
On day 21, the cells were rinsed and incubated in PBS containing 0.5 mM EDTA at 37 °C for 12 min, and then dissociated with Accutase at 37 °C for 25 min. The detached cells were washed with 1% BSA (Life Technologies)/PBS and stained with mouse anti-human CPM (Leica Microsystems, NCL-CPMm or Abcam; ab49278) at 4 °C for 15 min. Mouse isotype control IgG1 (Sigma-Aldrich; M5284) was used as a negative control for anti-human CPM.
The cells were then stained with Alexa Fluor 647-conjugated anti-mouse IgG (Life Technologies; A-31571) at 4 °C for 15 min and stained with propidium iodide (PI) after being washed twice with 1% BSA/PBS. Then CPM hi , CPM lo and CPM -cells were sorted by FACS Aria II or Aria III (BD Biosciences) after the removal of dead cells stained with PI.
Induction and passages of alveolar stem cells in fibroblastdependent alveolar organoids. Alveolarization medium was prepared from Ham's F12 (Wako) by supplementation with dexamethasone (50 nM) (Sigma-Aldrich), 8-Br-cAMP (100 nM; Biolog Life Science Institute), 3-isobutyl-1-methylxanthine (100 nM; Wako), KGF (100 ng/ml), 1% B-27 supplement, 0.25% BSA, HEPES (15 mM; Sigma-Aldrich), CaCl 2 (0.8 mM), 0.1% ITS premix (BD Biosciences) and 50 U/ml penicillin-streptomycin 17 .
We mixed 100 µl of Fig. 1k,l) .
We replaced 1 or 0.5 ml of alveolarization medium without Y27632 in each lower chamber of the 12-well or 24-well cell culture insert, respectively, until day 35. For isolation and passaging of alveolar stem cells, the cells were dissociated as described previously 17 Fibroblast-free induction of alveolar stem cells. We prepared FF alveolarization medium by supplementing CHIR99021 (3 µM), SB431542 (10 µM) and Y27632 (10 µM) to the alveolarization medium described for FD induction of alveolar stem cells. A total of 2.0 × 10 5 isolated CPM hi progenitor cells at day 21 were suspended in 250 µl of FF alveolarization medium and seeded onto a nonadherent surface well plate for 3D culture (Kuraray; SQ 200 100 NA; 96-well plate format) to form cell aggregates. The cell aggregates were centrifuged after incubation for 48 h at 37 °C, 5% CO 2 .
The pellets of cell aggregates were gently resuspended in 20 µl of precooled Matrigel and placed into a well of a 12-well cell culture plate (Corning). After incubation for 20 min, 1 ml of FF medium was added onto the Matrigel-embedded cell aggregates and replaced every 2 d.
Isolation of adult human AT2 cells from lung tissues. The use of human lung samples was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine. After obtaining informed consent, we obtained adult human lung tissues from the nontumorous, nonpleural parenchyma of surgical specimens from female patients aged 46, 64 and 70 years with lung tumors. AT2 cells were isolated as previously reported, with some modification 55 . Briefly, lung tissues were mechanically minced and dissociated with Dispase II (Wako), collagenase/Dispase (Sigma-Aldrich) and DNase I (Sigma-Aldrich) for 60 min at 37 °C. After being filtered through a 100-µm mesh, the cells were treated twice with red cell lysis buffer (Life Technologies), and then CD45 + cells were depleted by either magnetic-activated cell sorting or FACS. For depletion by magnetic-activated cell sorting, the dissociated cells were stained with mouse anti-human CD45 (eBioscience; 14- Immunofluorescence staining. For imaging of 2D cultures or cytospin slides, cells were fixed with 4% paraformaldehyde/PBS (Nacalai Tesque) for 15 min at RT. The cells were rinsed three times with PBS, then the fixed cells were permeabilized with 0.2% Triton X-100/PBS for 15 min and incubated with blocking solution consisting of 5% normal donkey serum (EMD-Millipore) and 1% BSA/PBS for 30 min at RT. The cells were then stained with primary antibodies in blocking solution for 30 min, washed three times with 1%BSA/PBS, and stained with secondary antibodies for 30 min. For AO imaging, samples were fixed with 4% paraformaldehyde/PBS for 20 min at RT and then incubated in 30% sucrose/PBS overnight at 4 °C. The samples were then embedded in OCT compound (Sakura Finetek) and frozen in liquid nitrogen. The frozen samples were cryosectioned into 10-µm slices, permeabilized and blocked as described above. The samples were then incubated with primary antibodies overnight at 4 °C and stained with secondary antibodies for 1 h at RT. Hoechst-33342 was added to the secondary antibody solution for nuclear counterstaining. Anti-ABCA3 was kindly provided by Professor Nobuya Inagaki 56 . The primary and secondary antibodies used in the present study are listed in Supplementary Table 10 .
We obtained immunofluorescence images with an inverted fluorescence microscope (Olympus; IX81) or a confocal microscope (Leica Microsystems; TCS SP8). For flow cytometry of SFTPC-GFP + cell-derived subpopulations, dissociated cells from AOs were stained with PE-conjugated anti-human EpCAM (BD Bioscience; 347198), APC-conjugated anti-human PDPN and PI and analyzed on a BD Aria II or III. PE-conjugated mouse IgG1 (Beckman Coulter) was used as an isotype control of PE-conjugated anti-EPCAM.
Whole-well imaging of AO formation. A whole-well image of an organoid on a 24-well cell culture insert was automatically divided into 63 parts under 200× magnification, sequentially recorded by BZ-9000 (Keyence), and reconstructed with the image-joint program of the BZ-X Analyzer software (Keyence).
Live cell imaging of lamellar bodies in AOs. hiPSC-derived AOs were incubated in alveolarization medium with β-BODIPY FL C 12 -HPC (1 µM) (Life Technologies; D-7392) for 24 h at 37 °C, 5% CO 2 . The organoids were then washed and incubated in alveolarization medium with LysoTracker Red DND-99 (100 nM) for 30 min at RT. After being washed twice, the samples were taken out of the cell culture inserts and observed by FV10i-LIV confocal microscopy (Olympus) at 37 °C, 5% CO 2 . The images were processed with Fluoview ASW software (Olympus).
Electron microscopy. Small pieces of chopped organoids or pellets of SFTPC-GFP + cells were incubated in fixative solution; then en bloc staining was performed with 1% uranyl acetate, dehydration and embedding in Epon 812 as previously reported 17 . Thin-slice samples were stained with uranyl acetate and lead citrate and observed by TEM (Hitachi; H-7650).
Drug toxicology study with hiPSC-derived AOs. hiPSC-derived FD-AOs (P2 or P3) were treated with GNE7915 (5 µM) or amiodarone (10 µM) from day 4 to day 14, with the medium changed every 2 d. For live cell imaging, AOs were incubated with LysoTracker Red and observed on day 14. For flow cytometry analysis, AOs were dissociated and stained with APC-conjugated anti-human EpCAM and LysoTracker Red. The signal intensity of LysoTracker was calculated with FlowJo software (FlowJo, LLC).
Microarray analysis. We cleaned up total RNA for the digestion of genomic DNA with DNase I with the NucleoSpin RNA Clean-up XS kit (Macherey-Nagel). Cy3-labeled cRNA was generated from 0.1 µg of total RNA with the Low Input Quick Amp labeling kit (Agilent Technologies) and purified on RNeasy columns (Qiagen). Labeled cRNA (0.6 µg) was fragmented and hybridized to SurePrint G3 Human Gene Expression 8×60K v2 microarrays (Agilent Technologies) for 17 h at 65 °C, in accordance with the manufacturer's instructions. The array slides were then scanned with a microarray scanner (Agilent Technologies; G2600D) and the images were processed with Feature Extraction software (Agilent Technologies). For the transcriptome analysis, the signal intensity for each gene was normalized and analyzed with GeneSpring GX 13.0 with baseline transformation to the median of all samples (Fig. 4f, Supplementary Fig. 8a,b) or the mean of control samples (Supplementary Fig. 15 ), or without baseline transformation (Fig. 4g, Supplementary Figs. 8c and 9) . We identified 740 genes with significantly upregulated expression in SFTPC-GFP + cells by analyzing each transcriptome of SFTPC-GFP + cells, SFTPC-GFP -cells, and CPM hi progenitor cells (n = 3 biological replicates each) with one-way ANOVA and Benjamini-Hochberg correction (P < 0.05, Tukey's post hoc test) and extracted the genes with more than twofold-increased expression in SFTPC-GFP + cells from among the three cell populations. GO enrichment analysis was performed on the 740 genes that were upregulated in SFTPC-GFP + cells with a cutoff P value of 0.05 as determined by Fisher's exact test. We carried out hierarchical clustering and PCA using the normalized expression data for P0, P2 and P5 FD-SFTPC + cells; CPM hi progenitor cells derived from B2-3 SFTPC-GFP + reporter hiPSCs; human adult primary AT2 cells; and parental 201B7 hiPSC-derived PAECs induced under 4-week Notch inhibition, as previously described 20 (n = 3 independent organoids each). We used Ward's linkage method with the Chebyshev distance measure for clustering. Pearson's correlation coefficient was used to validate the associations among samples on the original gene sets of lung epithelial cells with hierarchical clustering.
For the comparison of the transcriptomes of FD-SFTPC + cells and adult AT2 cells, 6,142 genes were detected as specifically upregulated in adult AT2 cells, defined as greater than twofold upregulation in adult AT2 cells compared with expression in P0, P2 and P5 FD-SFTPC + cells after subtraction of the genes that were upregulated by more than twofold in P0, P2 and P5 FD-SFTPC + cells compared with expression in CPM hi progenitor cells (P < 0.05, ANOVA corrected by Benjamini-Hochberg FDR with Tukey's post hoc test).
For analysis of drug toxicology, we evaluated 1,809 and 1,365 genes whose expression was significantly changed by treatment with GNE7915 and amiodarone, respectively (more than twofold change versus vehicle control; P < 0.05, t-test).
Single-cell RNA-seq. We used a BD Aria II cell sorter to isolate a total of 2.0 × 10 5 CPM hi cells on day 14, CPM hi cells treated with CFKD medium on day 21, EpCAM + cells after switching to alveolarization medium for AO induction on day 26, FF-SFTPC + cells on day 28 and FD-SFTPC + cells in P0, P2 and P5 AOs. The isolated cells in each condition were prepared at a concentration of 2.5 × 10 2 cells/µl for single-cell analysis. Single cells in each condition were captured and separated in each chamber of a medium-sized (10-17 µm) C1 integrated fluidic circuit (Fluidigm; #100-6041) with the C1 system (Fluidgm). First-strand cDNA was then synthesized and amplified in the independent chamber with a SMART-Seq v4 Ultra Low Input RNA kit for sequencing (Clontech; 634891) in accordance with the manufacturer's protocol. We prepared 200 cell-bulk control cDNAs for each condition. RNA spikein controls (spikes 1, 4 and 7) (Thermo Fisher Scientific; AM1780) were added to cell lysates before amplification in order to qualify the subsequent quantification in accordance with the manufacturer's protocol. Sequencing libraries were prepared with a Nextera XT kit (Illumina; FC-131-1096), and then 100-bp paired-end reads were sequenced on an Illumina HiSeq 2500.
Processing and analysis of scRNA-seq data. We used Illumina ELAND version 2 to align the 100-bp paired-end raw tags to the human reference genome sequences (hg19, UCSC) for each of the single-cell samples in six conditions (CPM hi cells at days 14 and 21; EpCAM + cells at day 26; and P0, P2 and P5 FD-SFTPC + cells). The tags that were uniquely aligned to the genome region (two base mismatches were permitted) were counted with normalization to the number of reads per million tags per kilobase of mRNA (RPKM). The average numbers of total and Ref-seq mapped tags that were counted in each condition are described in Supplementary Figures 5a, 6b and 12a . Single-cell samples that met both criteria (RPKM of each spike-in RNA control within the range of the mean ± two s.d., and tag counts of spike-in RNA controls with <30% of the total tag counts in each condition) were adapted as qualified samples for subsequent experiments. Singlecell samples with <100,000 Ref-seq mapped tags were excluded from analysis. We used Pearson's correlation analysis to compare the RPKM levels of 24,104 genes among each condition or between means of qualified single-cell samples and bulk controls in each condition. The cutoff value that defined 'SFTPC positive' was log 2 RPKM = 4. Single cells expressing both ACTB and GAPDH within the ±s.d. range for either of those genes were used for expression analysis. To obtain scRNA-seq data for adult AT2 cells, we aligned the downloaded sequence reads (GSE86618) 34 to hg19 and counted to the RPKM in the same manner used to process our own data. The cells expressing SFTPC with log 2 RPKM values of >4 from three healthy adults (CC002, CC006 and CC019) were used for analysis. We carried out hierarchical clustering analysis and PCA for genes detected with log 2 RPKM values of >0.5 in at least one sample. We used Ward's linkage method with Euclidean distance for clustering. All of the expression analyses were done with GeneSpring GX 13.0 (Agilent Technologies). KEGG pathway analysis was done with DAVID v6. 8 
(ref. 57).
Quantitative RT-PCR. Total RNA was extracted with a PureLink RNA mini kit (Life Technologies). cDNA was converted from 80 ng of total RNA with the SuperScript III First-Strand Synthesis System (Life Technologies). Amplified cDNA in the C1 system (Fluidigm) was used for single-cell qRT-PCR. The qRT-PCR was done on an ABI7300 Real-Time PCR System (Life Technologies) with Power SYBR PCR Master Mix (Life Technologies) as previously described 8 . Gene expression levels were normalized to that of ACTB and are presented relative to gene expression levels in human fetal lung at 17, 18 and 22 weeks of gestation (Agilent Technologies; #540177, lot 0006055802) or human fetal trachea at 29 weeks of gestation (Agilent Technologies; #R1244160-10, lot B402231). The primers used in this study are described in Supplementary Table 11. Statistics. No statistical estimation was performed to determine the adequacy of sample sizes. This study was not randomized and the researchers were not blinded. All error bars in figures indicate s.e.m. Two-tailed Student's t-test was used for comparisons between two groups. One-way ANOVA with Tukey's post hoc test was adopted for comparisons among three or more groups with normal distribution. Kruskal-Wallis test or Freedman's test, each of which was combined with Dunn's post hoc multiple-comparison test, was used for paired or nonpaired samples without normal distributions, respectively. Pearson's correlation coefficient was used for correlation analysis. P < 0.05 was considered to indicate statistical significance. All of the statistical analyses, with the exception of the whole-transcriptome analysis, were done with Prism 7 software (GraphPad). The mRNA microarray data and the single-cell RNA-seq data were analyzed with GeneSpring GX 13.0 software. Data availability. Data were deposited in the Gene Expression Omnibus (GEO) under accession numbers GSE90590, GSE90591 and GSE99939 for microarray data, and GSE90813 for scRNAseq data. A Life Sciences Reporting Summary for this paper is available.
